No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
HOTH Hoth Therapeutics
- 1.1600
- -0.0100-0.85%
Close Apr 26 16:00 ET
- 1.2500
- +0.0900+7.76%
Post 18:37 ET
5.67MMarket Cap-504P/E (TTM)
1.1900High1.1200Low48.96KVolume1.1500Open1.1700Pre Close56.90KTurnover1.13%Turnover RatioLossP/E (Static)4.89MShares4.300052wk High0.64P/B5.02MFloat Cap0.990052wk Low--Dividend TTM4.33MShs Float347.0000Historical High--Div YieldTTM5.98%Amplitude0.9900Historical Low1.1620Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Hoth Therapeutics Stockholders to Sell Up to 5.03M Shrs
Hoth Therapeutics Stockholders to Sell Up to 5.03M Shrs
Promising Preclinical Alzheimer's Candidate and Diverse Pipeline Bolster Hoth Therapeutics' Buy Rating
Express News | HC Wainwright & Co. Reiterates Buy on Hoth Therapeutics, Maintains $4 Price Target
Hoth Therapeutics Is Maintained at Buy by EF Hutton
Hoth Therapeutics Is Maintained at Buy by EF Hutton
Express News | EF Hutton Maintains Buy on Hoth Therapeutics, Raises Price Target to $7
Hoth Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 400% EF Hutton $6.5 → $7 Maintains Buy 02/05/2024 185.71% HC Wainwright & Co. → $4 Initiates Co
Comments
Medical Company Joins Forces With Artificial Intelligence Subsidiary
The Breakthrough in Obesity Treatment: How Merveille.ai is Changing the Game.
In an era where obesity has become a global epidemic, the quest for effective treatments has never been more urgent. Recent advancements in artificial intelligence (AI) have opened new doors in the fight against obesity, with Hoth Therapeutics' wholly-owned subsidiary Merveille.ai leading the charge. Their groundbreaking approach to discovering potenti...
In an era where obesity has become a global epidemic, the quest for effective treatments has never been more urgent. Recent advancements in artificial intelligence (AI) have opened new doors in the fight against obesity, with Hoth Therapeutics' wholly-owned subsidiary Merveille.ai leading the charge. Their groundbreaking approach to discovering potenti...
Another dealing with weight loss! Hehehe! If it was for cancer it would have gone down! Hehehe
$Hoth Therapeutics(HOTH.US$ Hoth Therapeutics' Merveille.ai Subsidiary Files Patent For Obesity Treatment And Begins Preparatory Steps For Clinical Trials; Merveille.ai Also Joins Nvidia Developer Program
Therapeutics Company Unveils Positive Results From Alzheimer's Research Study: Novel Treatment
Breakthrough in Alzheimer's Research: Hoth Therapeutics Unveils Promising Results from HT-ALZ Study.
In an era where the quest for effective Alzheimer’s treatments continues, Hoth Therapeutics has emerged as a beacon of hope with its recent announcement regarding the successful completion of a pre-clinical study for its novel treatment, HT-ALZ. This groundbreaking research could potentially alter the la...
In an era where the quest for effective Alzheimer’s treatments continues, Hoth Therapeutics has emerged as a beacon of hope with its recent announcement regarding the successful completion of a pre-clinical study for its novel treatment, HT-ALZ. This groundbreaking research could potentially alter the la...
News
$Hoth Therapeutics(HOTH.US$ Hoth Therapeutics Says HT-ALZ Emerges As A Promising Novel Solution For Combating Neuroinflammation And Cognitive Deficits Associated With Alzheimer's Disease.
Benzinga· 2 mins ago
Benzinga· 2 mins ago
Update
$Hoth Therapeutics(HOTH.US$ Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients
3 MINUTES AGO, 8:20 AM EST
VIA PR NEWSWIRE
3 MINUTES AGO, 8:20 AM EST
VIA PR NEWSWIRE
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg